# A Study of IMC-RON8 in Advanced Solid Tumors

> **NCT01119456** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 39 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8
- **BIOLOGICAL:** IMC-RON8

## Key facts

- **NCT ID:** NCT01119456
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119456, "A Study of IMC-RON8 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01119456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*